The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for dupilumab to treat adults with bullous pemphigoid.
Mirum Pharma's Ctexli has become the first FDA-approved therapy for cerebrotendinous xanthomatosis (CTX), an ultra-rare form ...
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts disc ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback